UK markets close in 8 hours 24 minutes

Biotest Aktiengesellschaft (BIO3.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
26.90-0.20 (-0.74%)
As of 5:36PM CEST. Market open.
Full screen
Previous close27.10
Open27.10
Bid26.70 x 53100
Ask26.90 x 20000
Day's range26.70 - 27.30
52-week range17.00 - 29.20
Volume5,940
Avg. volume9,396
Market cap1.066B
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)-0.69
Earnings dateN/A
Forward dividend & yield0.04 (0.15%)
Ex-dividend date11 May 2020
1y target est18.40
  • EQS Group

    Biotest AG: Biotest treats first COVID-19 patient with trimodulin

    DGAP-News: Biotest AG / Key word(s): Research Update06.10.2020 / 12:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest treats first COVID-19 patient with trimodulin- A clear reduction in mortality and in duration of ventilation support during intensive care stay is expected- Worldwide unique, innovative plasma protein preparation for treatment of COVID-19 patients- Expedited approval of trimodulin for COVID-19 intended Dreieich, 6 October 2020. Biotest announced today that the first patient with severe COVID-19 was treated in Spain with trimodulin in the ESsCOVID (Escape from severe COVID-19) trial. Furthermore has the trial been submitted for approval to the Regulatory Agencies in Russia, Brazil and now also in France.In this multinational phase II clinical trial, approximately 160 adult patients with severe COVID-19 are planned to be enrolled. These are patients with pneumonia or acute respiratory distress syndrome (ARDS) admitted to hospital due to the severity of their disease. After confirmation of SARS-CoV-2 infection and presence of a strong inflammatory response, the patients will be treated either with trimodulin or with placebo as add-on therapy to standard of care.The clinical concept of this prospective, double-blind, placebo-controlled phase II trial, was developed according to the expectations of the European Medicines Agency (EMA) after a so-called "Rapid Scientific Advice". Biotest aims for an expedited approval of trimodulin to rapidly respond to the need for novel treatment options for patients with severe COVID-19.Biotest's development product trimodulin is a worldwide unique, innovative antibody preparation. Trimodulin treatment has already demonstrated promising results in a phase II clinical trial with 160 invasive mechanically ventilated patients suffering from severe community-acquired pneumonia (sCAP) with a strong inflammatory response (CIGMA trial).The similarity of the COVID-19 symptoms to the patients treated in the CIGMA trial, justifies the hypothesis that trimodulin has a considerable potential in the treatment of SARS-CoV-2 induced pneumonia."We are very pleased, to be able to support physicians with trimodulin for the treatment of patients with severe COVID-19. We hope, that trimodulin will be able to prevent progression of disease and improve patient outcome. As this would also reduce to need for invasive mechanical ventilation, it could alleviate possible capacity limitations within intensive care units", said Daniela Zipp, responsible Head of Clinical Operations at Biotest.About COVID-19COVID-19 is a respiratory disease caused by the novel severe acute respiratory syndrome corona virus 2 variant (SARS-CoV-2). While most cases are mild or asymptomatic, COVID-19 patients may present at the hospital with typical signs of pneumonia requiring oxygen support. This disease stage is regularly accompanied by an excessive immune response and can lead to systemic inflammation reactions. Furthermore, patients may progress to critical disease with need for intensive care, including invasive mechanical ventilation. This clinical picture and course of the disease resembles that of sCAP caused by other pathogens.About trimodulin (IgM Concentrate)Biotest' development product trimodulin is an innovative immunoglobulin preparation, purified from human blood plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with severe COVID-19. Research so far has shown that trimodulin could interfere with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure, sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways. The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease, including the need for invasive mechanical ventilation and other intensive care procedures.About BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.IR contactDr Monika ButtkereitPhone: +49-6103-801-4406Mail: investor_relations@biotest.dePR contactDirk NeumüllerPhone: +49-6103-801-269Mail: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.06.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1139155   End of News DGAP News Service

  • EQS Group

    Biotest AG:

    DGAP-News: Biotest AG / Key word(s): Statement04.10.2020 / 20:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEDreieich, 4 October 2020. Bloomberg reported on 2 October 2020 that, according to informed circles, a private equity firm had approached the Chinese Creat Group Corp. to acquire a stake in Biotest AG. The consultations are at an early stage and there is no certainty that they will lead to a transaction.The company believes that this is pure market speculation.Such rumours and speculations are not new and are known to Biotest. The Management Board has therefore recently asked for a statement from the major shareholder on the plans with regard to the stake in the company. In a written communication to the Company, Creat Group Corp. has stated that no sale process has been initiated to date, nor has any decision been made regarding a future sale. The decision process regarding the future of the majority stake in Biotest AG is completely open, so that rumours of a sale are pure speculation.Biotest AG will continue to inform the capital market and the public in accordance with the legal requirements.About BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.ContactDirk NeumüllerPhone: +49-6103-801-269Mail: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.04.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1138735   End of News DGAP News Service

  • Bloomberg

    Triton Said to Pursue Stake in Creat’s Blood Plasma Unit Biotest

    (Bloomberg) -- Private equity firm Triton has approached China’s Creat Group Corp. about buying a stake in German blood-plasma supplier maker Biotest AG, according to people familiar with the matter.The European private equity firm has expressed interest in acquiring Biotest shares from Creat, the people said, asking not to be identified because the information is private.Biotest has a market value of about 1 billion euros ($1.2 billion). Creat owns about 90% of Biotest’s common stock, while its preference shares are held by other investors, according to data compiled by Bloomberg.Any deal would see the Chinese group start to unwind a series of overseas acquisitions that began in 2016, which also included a purchase of the U.K.’s Bio Products Laboratory Ltd. Creat was forced to sell Biotest’s U.S. operations following scrutiny from the Committee on Foreign Investment in the U.S.Deliberations are at an early stage, and there’s no certainty they will result in a transaction, the people said. A spokeswoman for Triton declined to comment. Calls to Creat’s office in Beijing weren’t answered outside regular business hours.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.